Dimensional Fund Advisors LP Sells 50,649 Shares of Pulmonx Co. (NASDAQ:LUNG)

Dimensional Fund Advisors LP cut its position in shares of Pulmonx Co. (NASDAQ:LUNG) by 12.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 345,074 shares of the company’s stock after selling 50,649 shares during the period. Dimensional Fund Advisors LP owned about 0.89% of Pulmonx worth $2,188,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Pulmonx by 0.6% during the first quarter. Vanguard Group Inc. now owns 2,077,859 shares of the company’s stock valued at $19,262,000 after purchasing an additional 11,417 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Pulmonx by 7.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock valued at $6,714,000 after purchasing an additional 69,595 shares during the period. Victory Capital Management Inc. increased its position in shares of Pulmonx by 1.0% during the second quarter. Victory Capital Management Inc. now owns 834,301 shares of the company’s stock valued at $5,289,000 after purchasing an additional 8,004 shares during the period. Bank of New York Mellon Corp increased its position in shares of Pulmonx by 12.7% during the second quarter. Bank of New York Mellon Corp now owns 157,902 shares of the company’s stock valued at $1,001,000 after purchasing an additional 17,740 shares during the period. Finally, Sei Investments Co. increased its position in shares of Pulmonx by 2.5% during the first quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock valued at $673,000 after purchasing an additional 1,800 shares during the period. 91.04% of the stock is currently owned by institutional investors.

Pulmonx Price Performance

Shares of LUNG stock opened at $6.67 on Friday. The stock’s fifty day simple moving average is $7.20 and its 200 day simple moving average is $7.46. The company has a debt-to-equity ratio of 0.37, a current ratio of 8.97 and a quick ratio of 7.92. The firm has a market cap of $261.13 million, a price-to-earnings ratio of -4.45 and a beta of 0.64. Pulmonx Co. has a one year low of $5.46 and a one year high of $14.84.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, July 31st. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.02. The business had revenue of $20.78 million for the quarter, compared to analyst estimates of $20.23 million. Pulmonx had a negative return on equity of 50.79% and a negative net margin of 75.56%. On average, analysts expect that Pulmonx Co. will post -1.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Pulmonx news, insider Geoffrey Beran Rose sold 4,586 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.70, for a total value of $30,726.20. Following the transaction, the insider now owns 295,433 shares of the company’s stock, valued at approximately $1,979,401.10. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Pulmonx news, Director Glendon E. French III sold 20,000 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $8.09, for a total value of $161,800.00. Following the transaction, the director now owns 1,111,974 shares of the company’s stock, valued at approximately $8,995,869.66. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Geoffrey Beran Rose sold 4,586 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.70, for a total value of $30,726.20. Following the completion of the transaction, the insider now directly owns 295,433 shares in the company, valued at approximately $1,979,401.10. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,351 shares of company stock valued at $231,094. 5.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on LUNG. Wells Fargo & Company lowered their price objective on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Canaccord Genuity Group boosted their price target on Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $14.83.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.